RASGRF2 and breast neoplasm: Given that activation of RasGRF2 by Ca2+ mobilizing oncogenes constitutes an important axis for Ras activation by several RTKs and GPCRs, this study provides a strong rationale to target these hard-to treat breast tumors with EGFR targeted therapies in combination with inhibition of RasGRF2.